Physician profile
Andrew C Ko
NPI 1437170990
$1,770.48
in general payments reported to CMS, 2019-2025
14 companies · $972 in 2025
The $972 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2021: $12.23 · 2022: $149 · 2023: $319 · 2024: $119 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,409.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $252.41 | 2023-2025 | Tremfya, Stelara |
| Endogastric Solutions, INC | $213.70 | 2019-2023 | Esophyx |
| Medtronic, INC. | $142.85 | 2025 | Barrx |
| Boston Scientific Corporation | $142.35 | 2022-2025 | Overstitch Endoscopic Suturing System |
| Abbvie INC. | $124.88 | 2025 | |
| Aimmune Therapeutics, INC. | $124.88 | 2025 | Zenpep |
| Gilead Sciences, INC. | $121.63 | 2025 | Livdelzi |
| Genzyme Corporation | $120.39 | 2022 | |
| Intercept Pharmaceuticals, INC. | $118.88 | 2024 | |
| Lilly USA, LLC | $118.45 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $115.32 | 2023 | Zeposia |
| Celltrion USA INC. | $94.88 | 2025 | Zymfentra |
| Amgen INC. | $54.58 | 2019 | |
| Glaxosmithkline, LLC. | $25.28 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.